Biocon Secures European Commission Approval for Pertuzumab Biosimilar Pebrilzo in HER2-Positive Breast Cancer
Biocon's pertuzumab biosimilar Pebrilzo wins European Commission approval for HER2-positive breast cancer, the first under EMA's revised clinical pathway.
Research Desk
The European Commission has awarded marketing authorization to Pebrilzo, Biocon Limited's biosimilar version of pertuzumab, for the treatment of HER2-positive breast cancer at multiple disease stages within the European Union.
Announced by Biocon, the decision makes the product the first pertuzumab biosimilar to win EC approval under the European Medicines Agency's new tailored clinical approach.
Pertuzumab Becomes Fifth Dual-Approved Oncology Biosimilar
The authorization follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) issued on September 17, 2026, and arrives shortly after the same biosimilar was approved by the U.S. Food and Drug Administration.
Shreehas Tambe, CEO and Managing Director of Biocon, described the EC approval as a significant regulatory milestone for the company.
He noted that pertuzumab now stands as Biocon's fifth oncology biosimilar to be approved in both Europe and the United States, a development the company says strengthens its global oncology portfolio and its push to expand access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.
What the Approval Covers
Pebrilzo is authorized as a 420 mg concentrate for solution for infusion.
Its active substance, pertuzumab, is a monoclonal antibody that binds with high affinity and specificity to human epidermal growth factor receptor 2 (HER2), thereby inhibiting the proliferation of tumour cells that overexpress HER2. The approved indications span three treatment settings.
The biosimilar may be used in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence. It is also cleared for adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
A third indication covers use with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not previously received anti-HER2 therapy or chemotherapy for metastatic disease.
Biocon stated that extensive orthogonal, state-of-the-art structural and functional analytical characterisation, alongside comparative clinical pharmacokinetic data, showed the biosimilar to be highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.
Disease Landscape the Product Enters
Breast cancer is the most commonly diagnosed cancer among women in Europe. Under 2024 estimates from the European Cancer Information System (ECIS), it is the leading cancer diagnosis among women across the region.
Roughly 15 to 20 percent of invasive breast cancers are characterised by HER2 overexpression or amplification. Biocon noted that, despite considerable progress in HER2-targeted treatment, the scale of the disease highlights the need for broad and sustainable access to high-quality treatment options across European healthcare systems.
Position Within Biocon's Oncology Strategy
According to Biocon, the EC authorization is intended to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe.
The company views the approval as reinforcing its growing oncology portfolio and its focus on evolving patient and healthcare needs. Biocon's oncology work extends across several areas of cancer care, covering solid tumors such as breast cancer and supportive care for chemotherapy-induced neutropenia.
The portfolio also addresses bone health, including osteoporosis, treatment-related bone loss, and skeletal complications linked to advanced cancers. The company said biosimilar pertuzumab adds to its capacity to support patients at different stages of the cancer care journey and across diverse healthcare systems.
The Company Behind the Product
Biocon Limited, listed on the BSE (532523) and NSE (BIOCON), is a global biopharmaceutical company headquartered in Bengaluru, India, with a stated purpose of providing affordable, life-changing medicines to patients worldwide.
The company addresses chronic and non-communicable diseases through biosimilars and generics offered at scale, concentrating on areas of high unmet need such as diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health.
Biocon has commercialized 12 biosimilar products and more than 30 generic formulations globally. Its research and development pipeline contains more than 20 biosimilar assets along with GLP-1 peptides and other complex generics.
Operating an integrated lab-to-patient model that combines research and development, manufacturing, and commercial capabilities, the company says it ensures a reliable and scalable supply of medicines.
Biocon is present in more than 120 countries through seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce exceeding 9,500 employees. The company has appeared in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year.
Tracked in the database
Pharmaceutical Regulatory Approvals · Europe
Pharmaceutical Regulatory Approvals
Europe
Chemical
18 November 2026
3 min read
Tagged
Also read
Teva Secures U.S. Rights to Two Samsung Bioepis Immunology Biosimilars Under 2026 Licensing Deal
Nanoform Partners With European CDMO to Manufacture High-Concentration Biologics Under GMP in Germany
LOTTE Biologics Signs First Commercial Manufacturing Agreement for Songdo Plant 1 in South Korea
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.